Cross-Sector entity

Silk Road Medical

Company
5

All 1 tracked stories fall under one category: pharma. Silk Road Medical is most often covered alongside Axonics, which appears in 1 of these 1 story. We currently track 1 Cross-Sector story that mention Silk Road Medical, all published on March 23, 2026.

1 verified story tracked

Last mentioned: Mar 23, 2026

Entity pulse

Recent coverage · Silk Road Medical

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Silk Road Medical

All 1 tracked stories fall under one category: pharma. Silk Road Medical is most often covered alongside Axonics, which appears in 1 of these 1 story. We currently track 1 Cross-Sector story that mention Silk Road Medical, all published on March 23, 2026. Each carries 2 original sources on average.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Silk Road Medical. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Lead Plaintiff Deadline

    Expected deadline for shareholders to petition the court to serve as lead plaintiff in the case.

  2. Follow-up Disclosure

    Secondary announcements highlight the filing and the process for shareholders to join the litigation.

  3. Class Action Announcement

    Pomerantz LLP first alerts investors to the class action filing against Boston Scientific.

Stories mentioning Silk Road Medical 1

Biotech pharma Neutral 5

Boston Scientific Faces Class Action Scrutiny Over Securities Disclosures

Pomerantz LLP has initiated a class action lawsuit against Boston Scientific (BSX), alleging potential violations of federal securities laws. The litigation centers on the company's disclosures during a period of significant expansion and product integration, marking a critical legal challenge for the medical device giant.

2 sources